Companies: 10,795·Total market cap: $144.5T
Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd.

GLMDNASDAQHealthcare● Active
$0.47
$-0.23(-32.57%)
Market Cap$2571403
P/E Ratio—
52W High$2.34
52W Low$0.411
SEC Filings
Foreign Private Issuer · Files 20-F / 6-K

Galmed Pharmaceuticals Ltd. (GLMD) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001595353 · GLMD · NASDAQ · as of Jun 8, 2026

Filing snapshot

362
Total Filings
POS EX
Latest Form
2026-06-08
Most Recent
2014
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001595353 · Updated hourly · Not investment advice

Latest Annual Report

20-F · Annual Report (Foreign Issuer)FY
Filed Date
2026-03-31
Fiscal Year End
Mar 31, 2026
Accession No.
0001493152-26-014182
Primary Document
form20-f.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001595353 · Accession 0001493152-26-014182

Latest Key Filings

6-KQuarterly Report
6-K
2026-06-08
View 6-K on SEC
8-KCurrent Report

No recent filings

Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
POS EXPOS EX
POS EX
2026-06-08
View
424B3424B3
424B3
2026-06-08
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-06-08
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-06-02
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-05-14
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-05-06
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-04-14
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-04-09
View
EFFECTEFFECT
EFFECT
2026-04-01
View
POS AMPOS AM
POS AM
2026-03-31
View
20-FAnnual Report (Foreign Issuer)
20-F
2026-03-31
View
3Initial Statement of Beneficial Ownership
3
2026-03-18
View
3Initial Statement of Beneficial Ownership
3
2026-03-18
View
3Initial Statement of Beneficial Ownership
3
2026-03-18
View
3Initial Statement of Beneficial Ownership
3
2026-03-18
View
Showing 1–15 of 362 filingsForm 4 / 144 hidden

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001595353  |  Exchange: NASDAQ · Healthcare

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) has submitted 362 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2014. As a Healthcare sector company with CIK 0001595353, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Galmed Pharmaceuticals Ltd.'s most comprehensive regulatory disclosure. The most recent Galmed Pharmaceuticals Ltd. 10-K was filed on 2026-03-31 for fiscal year ending 2026. Historical GLMD 10-K annual reports are available from 2013 through 2026.

Investors researching Galmed Pharmaceuticals Ltd. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
BIVI SEC Filings →CMMB SEC Filings →TOVX SEC Filings →NKGN SEC Filings →MLEC SEC Filings →ELAB SEC Filings →INM SEC Filings →VRAX SEC Filings →
→ GLMD Financials→ GLMD Earnings→ GLMD Insider Trades

Frequently Asked Questions

GLMD SEC Filings · 8 questions

Galmed Pharmaceuticals Ltd. (GLMD) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 362 filings and access original documents at no cost. Galmed Pharmaceuticals Ltd.'s CIK is 0001595353.

GLMD SEC filingsGalmed Pharmaceuticals Ltd. SEC documentsfind GLMD 10-K